New England Research & Management Inc. Buys Shares of 1,550 Natera, Inc. $NTRA

Key Points

• New England Research & Management Inc. acquired a stake in Natera, Inc., purchasing 1,550 shares valued at approximately $262,000 in the second quarter of the year.
• Analysts remain optimistic about Natera, with multiple firms giving buy ratings and target prices ranging from $183 to $210, collectively indicating a strong positive outlook.
• In recent insider trading, CFO Michael Burkes Brophy sold 3,045 shares, reflecting a 4.45% reduction in his ownership, while corporate insiders have collectively sold $8.46 million worth of shares in the last ninety days.

New England Research & Management Inc. acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,550 shares of the medical research company's stock, valued at approximately $262,000.

Other hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new position in shares of Natera in the 1st quarter worth approximately $29,000. Rakuten Securities Inc. grew its position in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. TCTC Holdings LLC grew its position in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares in the last quarter. ORG Partners LLC acquired a new position in shares of Natera in the 1st quarter worth approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after acquiring an additional 106 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Activity at Natera

In other news, insider John Fesko sold 678 shares of Natera stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the transaction, the insider owned 152,747 shares in the company, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 over the last ninety days. Company insiders own 5.63% of the company's stock.

Natera Stock Up 0.7%

NTRA stock traded up $1.25 during trading on Friday, reaching $181.11. 1,489,046 shares of the company's stock were exchanged, compared to its average volume of 858,746. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00. The company's fifty day moving average price is $156.80 and its 200-day moving average price is $155.04. The firm has a market cap of $24.86 billion, a PE ratio of -94.82 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the firm posted ($0.30) EPS. The firm's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Stephens reiterated an "overweight" rating and issued a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Piper Sandler restated an "overweight" rating and set a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Barclays restated an "overweight" rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Morgan Stanley restated an "overweight" rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Finally, Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of "Buy" and a consensus target price of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.